MeSH D002312 - hypertrophic cardiomyopathy
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D009202:Cardiomyopathies
0 Companies
0 Drugs
Success rate
D001020:Subvalvular aortic stenosis
0 Companies
0 Drugs
Success rate
D024741:Hypertrophic cardiomyopathy familial
0 Companies
0 Drugs
Success rate
D000092183:Apical hypertrophic cardiomyopathy
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Bristol Myers Squibb | Mavacamten | Camzyos | 2023-06-26 | $467 M | Q4/23-Q3/24 |
Clinical Trials
Historical Success Rate
Phase 1
67%2/3
Phase 2
44%7/16
Phase 3
0%0/8
Approved: 0Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use